Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir and Ribavirin in Chronic HCV with Cirrhosis and Portal Hypertension
NCT01687257Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial in hepatitis C (HCV) comparing SOF+RBV with Observation, then SOF+RBV (2 arms). Primary endpoint: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy. Started Jul 2012; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01687257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01687257.